Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy in Sarcoma: Current Data and Promising Strategies
Georgina Wood, Christian F. Meyer, Florent Petitprez, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 10

Showing 10 citing articles:

Botensilimab (Fc-enhanced anti–cytotoxic lymphocyte-association protein-4 antibody) Plus Balstilimab (anti–PD-1 antibody) in Patients With Relapsed/Refractory Metastatic Sarcomas
Breelyn A. Wilky, Gary K. Schwartz, Michael S. Gordon, et al.
Journal of Clinical Oncology (2025)
Closed Access | Times Cited: 1
Preclinical models of soft tissue sarcomas – generation and applications to enhance translational research
Sandro Pasquali, David S. Moura, Mary K. Danks, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 207, pp. 104621-104621
Open Access
Case Report: Lasting complete response to pembrolizumab in mismatch repair-deficient cardiac sarcoma: a genomic characterization
Daniela A. Ferraro, Bettina Bisig, David C. Rotzinger, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies
Qing Zhang, Zhe Wang, Xueqin Zeng, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Ibero-American Consensus for the Management of Liver Metastases of Soft Tissue Sarcoma: Updated Review and Clinical Recommendations
Raquel Lopes-Brás, Paula Muñoz, E. Netto, et al.
Cancers (2025) Vol. 17, Iss. 8, pp. 1295-1295
Open Access
Myeloid Cells in the Immunosuppressive Microenvironment as Immunotargets in Osteosarcoma
Cyrus Sholevar, Natalie M Liu, Tasneem Mukarrama, et al.
ImmunoTargets and Therapy (2025) Vol. Volume 14, pp. 247-258
Open Access
Review of Adoptive Cellular Therapies for the Treatment of Sarcoma
James J. Fradin, John Charlson
Cancers (2025) Vol. 17, Iss. 8, pp. 1302-1302
Open Access
Pathogenetic and molecular classifications of soft tissue and bone tumors: A 2024 update
Andrei Patrichi, Simona Gurzu
Pathology - Research and Practice (2024) Vol. 260, pp. 155406-155406
Open Access | Times Cited: 2
Evaluation of tumorous LCP1 and ADPGK as predictive biomarker for immune-related adverse events in bone and soft tissue sarcomas treated with anti-PD-1 and anti-PD-L1 antibodies
Qing Zhang, Zhe Wang, Xueqing Zeng, et al.
Research Square (Research Square) (2024)
Closed Access
A study of pre- and post-treatment hematologic markers of immune response in patients undergoing radiotherapy for soft tissue sarcoma
Eric Ku, Garrett K. Harada, Grace Lee, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access
Targeting heparanase/heparan sulfate proteoglycans by non‐anticoagulant heparins: Opportunities for innovative therapeutic approaches in sarcomas
Cinzia Lanzi, Sandro Pasquali, Giuliana Cassinelli
Proteoglycan Research (2024) Vol. 2, Iss. 4
Open Access
Page 1

Scroll to top